iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Ipca Laboratories: Valuations factoring-in too much optimism

13 Nov 2023 , 11:36 AM

The Street seems to have discounted execution risks in Ipca’s Rs15bn acquisition of Unichem and is factoring-in too much of optimism on mgmt’s ability to turnaround Unichem and scale back Ipca’s US business to its historical levels post the recent USFDA clearance of the 3 plants. Analysts of IIFL Securities note that despite Unichem’s revenue growing >30% in H1FY24, Unichem’s Ebitda margins continue to remain paltry at 4-5% implying limited operating leverage in the business. Additionally, Ipca’s erstwhile US product portfolio would have also seen price erosion over the past 8-year period, thereby raising doubts on whether Ipca can ramp-up its US business significantly in the near-term. Despite giving benefit of doubt and assuming that Ipca can increase Unichem’s Ebitda to Rs3.4bn in FY26ii, scale-up its US business to USD30m in 2 years, and improve base margins (ex-Unichem) by 170bps over FY24-26, analysts of IIFL Securities find no margin of safety in Ipca’s current valuations of 29/23x FY25/26 PE. They maintain their REDUCE rating with a TP of Rs930. 

Reiterated target of Rs3bn Ebitda from Unichem in 2 years: 

Unichem acquisition contributed for 2 months in Q2, with revenue/Ebitda of Rs2.85bn/60m. Ipca’s short-term targets for improving Unichem’s profitability include changes in API processing to expand GMs, reduce utility costs by Rs120-140m in FY24, and reign-in logistics costs. Medium-term targets include market expansion opportunities for Unichem’s API/ Formulation products, integration into Ratlam plant to improve cost efficiencies, & improve utilization across Ghaziabad/Goa plants. Analysts of IIFL Securities assume Unichem’s Ebitda to increase from Rs380m in H1FY24 to Rs3.4bn in FY26. 

Ipca’s US product supplies are expected to begin from Q1FY25, given revalidation of batches will take 4-5 months. Mgmt believes that there has not been any significant price erosion in Ipca’s erstwhile US portfolio. With 18 approvals and 26 pending ANDAs (mostly from Pithampur), mgmt is hopeful of ramping-up the US business, which will also be aided by Unichem’s US portfolio of 60-70 ANDAs. Analysts of IIFL Securities assume Ipca’s US sales of USD15/30m in FY25/26. R&D will increase from 2.5% to 4% gradually. 

Analysts of IIFL Securities have already assumed Ipca’s base business Ebitda margins (exUnichem) to expand ~170bps over FY24-26, driven by a consistent 13-14% growth in the India formulations business and 18% growth in the Export formulations led by the comeback of the US business. Although analysts of IIFL Securities see execution risks, they have upgraded FY24-26 Ebitda by 4-9%.

Related Tags

  • IPCA Laboratories
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp